Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Asthma III: Clinical Manifestations

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Filling the fellowship gap: A structured program for pharmacy students.

Currents in pharmacy teaching & learning·2026

Same author

Comment on "Adopting Race-Free Estimated Glomerular Filtration Rate for Unifying Medication-Related Decision-Making: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy".

Journal of the American College of Clinical Pharmacy : JACCP·2026

Same author

Game-Based Learning Effects on Student Engagement and Outcomes in Clinical Therapeutics Courses.

American journal of pharmaceutical education·2025

Same author

A Four-day Pharmacy Course Schedule.

American journal of pharmaceutical education·2023

Same author

Residents' assessment of mentoring received on lecture performance in a teaching and learning curriculum program.

Currents in pharmacy teaching & learning·2022

Same author

Evaluation of a risk assessment model to predict infection with healthcare facility-onset Clostridioides difficile.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2021

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Confirmed beta16 Arg/Arg polymorphism in a patient with uncontrolled asthma.

Nicole L Metzger¹, Denise R Kockler, Leigh Anne Hylton Gravatt

¹Virginia Commonwealth University Health System, Medical College of Virginia Hospitals, Richmond, VA 23298, USA.

The Annals of Pharmacotherapy

|April 24, 2008

Summary

Patients with the beta(16) Arg/Arg polymorphism may experience uncontrolled asthma with short-acting beta(2)-agonists. Genotyping and considering anticholinergics may improve asthma outcomes in these individuals.

Related Experiment Videos

Last Updated: Jul 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

Pharmacogenomics
Respiratory Medicine
Clinical Genetics

Background:

Uncontrolled asthma necessitates exploring genetic factors influencing treatment response.
The beta(16) Arg/Arg polymorphism is prevalent in certain populations and may impact beta-agonist efficacy.

Observation:

A patient with uncontrolled asthma and frequent short-acting beta(2)-agonist (SABA) use was found to have the beta(16) Arg/Arg genotype.
Despite adherence to asthma medications, the patient experienced multiple exacerbations requiring hospitalization and intubation.

Findings:

The beta(16) Arg/Arg genotype is associated with a potential decrease in sensitivity or increased desensitization to beta(2)-agonists.
Clinical outcomes, including asthma symptoms and exacerbations, may worsen with regular SABA use in individuals with this polymorphism.

Implications:

Beta(2)-adrenoreceptor genotyping can identify patients at risk for poor outcomes with standard asthma therapies.
Anticholinergic medications may offer a beneficial alternative to beta(2)-agonists as a primary rescue therapy for patients with the Arg/Arg polymorphism.